Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02741323 · ClinicalTrials.gov registry record · Phase 2
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
A Phase 2 study of HIV Infections and Kidney Diseases, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 10
- Study locations
NCT02741323: Completed Phase 2 study of HIV Infections and Kidney Diseases, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02741323 is a Phase 2 study of HIV Infections and Kidney Diseases that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 97 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02741323, a Phase 2 study of HIV Infections and Kidney Diseases, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 10
- Study locations
Study Summary
Maraviroc (MVC) is a type of HIV medicine called a CCR5 inhibitor. This study will evaluate the safety and tolerability of MVC in HIV-infected adults receiving a kidney transplant.
Primary Outcome
The primary efficacy endpoint is the 52-week GFR as measured by iohexol clearance
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maraviroc
Study Locations (10)
California
- UCLA HIVTR-CCR5 Non-Network CRS - Los Angeles
- UCSF HIVTR-CCR5 Non-network CRS - San Francisco
Maryland
- Univ. of Maryland HIVTR-CCR5 Non-Network CRS - Baltimore
- JHU HIVTR-CCR5 Non-Network CRS - Baltimore
Alabama
- UAB HIVTR-CCR5 Non-Network CRS - Birmingham
District of Columbia
- Georgetown HIVTR-CCR5 Non-Network CRS - Washington D.C.
Georgia
- Emory HIVTR-CCR5 Non-Network CRS - Atlanta
Illinois
- Northwestern HIVTR-CCR5 Non-Network CRS - Chicago
New York
- Mt. Sinai Med. Ctr. HIVTR-CCR5 Non-Network CRS - New York
Pennsylvania
- Univ. of Penn HIVTR-CCR5 Non-network CRS - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2022-05-10 |
| Phase | Phase 2 |
What the finished NCT02741323 record still lists
NCT02741323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02741323 lists 10 locations in 8 states (California, Maryland, Alabama).
Frequently Asked Questions
What is clinical trial NCT02741323 about?
NCT02741323 is a clinical study titled "Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients". Maraviroc (MVC) is a type of HIV medicine called a CCR5 inhibitor. This study will evaluate the safety and tolerability of MVC in HIV-infected adults receiving a kidney transplant.
What is the current status of trial NCT02741323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2017-01-01. Estimated completion is 2022-05-10.
What conditions does trial NCT02741323 study?
This clinical trial studies the following conditions: HIV Infections, Kidney Diseases.
What interventions are being tested in trial NCT02741323?
The interventions under investigation include: Placebo (DRUG), Maraviroc (DRUG).
Who is sponsoring clinical trial NCT02741323?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02741323 being conducted?
This trial has 10 study locations across Alabama, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02741323's enrollment target sits among peer trials
97 278th of 542 higher than 265 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI